Literature DB >> 29934621

The optimal blood pressure target in diabetes mellitus: a quest coming to an end?

Eirini Papadopoulou1,2, Elena Angeloudi3, Spiridon Karras3, Pantelis Sarafidis4.   

Abstract

The presence of hypertension in patients with diabetes mellitus (DM) substantially increases cardiovascular risk. Blood pressure (BP) decrease in these individuals is associated with large reductions in cardiovascular morbidity and mortality, but the optimal BP levels in DM still remain a matter of important controversy. For almost 20 years, guidelines recommended an office BP target of <130/80 mmHg in diabetic individuals, following evidence from trials randomizing patients to diastolic BP levels. When the action-to-control-cardiovascular-risk-in-diabetes-blood-pressure (ACCORD-BP) study showed that systolic BP (SBP) <120 mmHg was associated with similar risk to SBP < 140 mmHg in type 2 DM, all guidelines stepped back to recommend a SBP < 140 mmHg, despite the obvious limitations of ACCORD-BP, including the surprisingly low event rate and the actual average BP of 133.5/70.5 mmHg in the "standard-target" arm. In contrast, the systolic-blood-pressure-intervention-trial (SPRINT) showed cardiovascular benefits in hypertensive patients without DM randomized to SBP<120 versus <140 mmHg and many believed that absence of between-group differences in ACCORD-BP was rather a matter of power and not of dissimilar cardiovascular profile of diabetic patients. In this regard, the American-College-of-Cardiology/American-Heart-Association 2017 BP guidelines advocated a BP target of <130/80 in all hypertensives, including those with DM. However, the 2018 American-Diabetes-Association recommendations were not in the same direction, suggesting BP goal <140/90 for most patients, with the exception of those with "high cardiovascular risk", where a <130/80 mmHg target may apply. This review presents the evidence from old and recent trials relevant to optimal BP levels in DM, aiming to shed light in this major clinical question.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29934621     DOI: 10.1038/s41371-018-0079-5

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  54 in total

1.  Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.

Authors:  Sripal Bangalore; Sunil Kumar; Iryna Lobach; Franz H Messerli
Journal:  Circulation       Date:  2011-05-31       Impact factor: 29.690

Review 2.  Snapshot Hemodynamics and Clinical Outcomes in Hypertension: Precision in the Measurements Is Key.

Authors:  Jay A Pandit; Daniel Batlle
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

3.  Redefining Blood-Pressure Targets--SPRINT Starts the Marathon.

Authors:  Vlado Perkovic; Anthony Rodgers
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

Review 4.  Cardiometabolic syndrome and chronic kidney disease: what is the link?

Authors:  Panteleimon A Sarafidis; Adam Whaley-Connell; James R Sowers; George L Bakris
Journal:  J Cardiometab Syndr       Date:  2006

Review 5.  The burden of blood pressure-related disease: a neglected priority for global health.

Authors:  Vlado Perkovic; Rachel Huxley; Yangfeng Wu; Dorairaj Prabhakaran; Stephen MacMahon
Journal:  Hypertension       Date:  2007-10-22       Impact factor: 10.190

Review 6.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 7.  Has the SPRINT trial introduced a new blood-pressure goal in hypertension?

Authors:  Gema Ruiz-Hurtado; José R Banegas; Pantelis A Sarafidis; Massimo Volpe; Bryan Williams; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

Review 8.  Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.

Authors:  Pantelis A Sarafidis; Antonios A Lazaridis; Gema Ruiz-Hurtado; Luis M Ruilope
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

9.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

10.  Executive summary: Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

View more
  2 in total

1.  Antihypertensive Medication Use and Its Effects on Blood Pressure and Haemodynamics in a Tri-ethnic Population Cohort: Southall and Brent Revisited (SABRE).

Authors:  Alun D Hughes; Sophie V Eastwood; Therese Tillin; Nish Chaturvedi
Journal:  Front Cardiovasc Med       Date:  2022-01-14

2.  Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non-diabetic CKD.

Authors:  Charalampos Loutradis; Maria Schoina; Theodoros Dimitroulas; Michael Doumas; Alexandros Garyfallos; Asterios Karagiannis; Aikaterini Papagianni; Pantelis Sarafidis
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-30       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.